Stem cell markers: A guide to neoadjuvant therapy in breast carcinomas
Aim: This study aims to investigate potential associations between the stem cell population and the degree of tumor regression in breast carcinomas treated with neoadjuvant therapy. Settings and Design: The study included 92 patients with breast carcinoma who received neoadjuvant therapy. Tumor regr...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-07-01
|
| Series: | Indian Journal of Pathology and Microbiology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ijpm.ijpm_1274_21 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206172969336832 |
|---|---|
| author | Zuhal Gucin Nur Buyukpinarbasili Melin Ozgun Gecer Yeliz Emine Ersoy Haci Mehmet Turk Seyma Yildiz Direnc Ozlem Aksoy |
| author_facet | Zuhal Gucin Nur Buyukpinarbasili Melin Ozgun Gecer Yeliz Emine Ersoy Haci Mehmet Turk Seyma Yildiz Direnc Ozlem Aksoy |
| author_sort | Zuhal Gucin |
| collection | DOAJ |
| description | Aim:
This study aims to investigate potential associations between the stem cell population and the degree of tumor regression in breast carcinomas treated with neoadjuvant therapy.
Settings and Design:
The study included 92 patients with breast carcinoma who received neoadjuvant therapy. Tumor regression was defined based on Miller and Payne grading system. Patients with grade 1 or 2 regression on a 5-point scale were included in group 1 (n = 37), grade 3 regression in group 2 (n = 32), and grade 4 or 5 regression in group 3 (n = 23).
Materials and Methods:
Immunohistochemical staining was performed on paraffin block sections of every case using CD44, CD24, CD29, CD133, ID4, and ALDH1 antibodies to detect stem cells.
Statistical Analysis Used:
IBM Statistical Package for the Social Sciences (SPSS), version 23.0 (IBM Corp., Armonk, NY, USA) software was used for statistical analyses, and a P value less than 0.05 was considered statistically significant.
Results:
Histologically high-grade tumors are more common in the near-complete/complete response group (P = 0.004). HER2-positive tumors were more common in the complete/near-complete response group (P = 0.054). Tumor cells positive for stem cell markers CD44 and CD24 were more common in the poor response group (P = 0.027 and P = 0.001, respectively). CD29 expression was reduced in the posttreatment residual tumor tissue in the near-complete/complete response group.
Conclusion:
High CD44 and CD24 expression may be a predictor of poor response/nonresponse to neoadjuvant therapy in breast carcinomas.
Background:
In recent years, stem cells have been defined as the main cell population responsible for resistance to anticancer therapies. |
| format | Article |
| id | doaj-art-a08bf18e088540ffa9c83be415fa30a9 |
| institution | Kabale University |
| issn | 0377-4929 |
| language | English |
| publishDate | 2023-07-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Pathology and Microbiology |
| spelling | doaj-art-a08bf18e088540ffa9c83be415fa30a92025-02-07T13:30:35ZengWolters Kluwer Medknow PublicationsIndian Journal of Pathology and Microbiology0377-49292023-07-0166349550110.4103/ijpm.ijpm_1274_21Stem cell markers: A guide to neoadjuvant therapy in breast carcinomasZuhal GucinNur BuyukpinarbasiliMelin Ozgun GecerYeliz Emine ErsoyHaci Mehmet TurkSeyma YildizDirenc Ozlem AksoyAim: This study aims to investigate potential associations between the stem cell population and the degree of tumor regression in breast carcinomas treated with neoadjuvant therapy. Settings and Design: The study included 92 patients with breast carcinoma who received neoadjuvant therapy. Tumor regression was defined based on Miller and Payne grading system. Patients with grade 1 or 2 regression on a 5-point scale were included in group 1 (n = 37), grade 3 regression in group 2 (n = 32), and grade 4 or 5 regression in group 3 (n = 23). Materials and Methods: Immunohistochemical staining was performed on paraffin block sections of every case using CD44, CD24, CD29, CD133, ID4, and ALDH1 antibodies to detect stem cells. Statistical Analysis Used: IBM Statistical Package for the Social Sciences (SPSS), version 23.0 (IBM Corp., Armonk, NY, USA) software was used for statistical analyses, and a P value less than 0.05 was considered statistically significant. Results: Histologically high-grade tumors are more common in the near-complete/complete response group (P = 0.004). HER2-positive tumors were more common in the complete/near-complete response group (P = 0.054). Tumor cells positive for stem cell markers CD44 and CD24 were more common in the poor response group (P = 0.027 and P = 0.001, respectively). CD29 expression was reduced in the posttreatment residual tumor tissue in the near-complete/complete response group. Conclusion: High CD44 and CD24 expression may be a predictor of poor response/nonresponse to neoadjuvant therapy in breast carcinomas. Background: In recent years, stem cells have been defined as the main cell population responsible for resistance to anticancer therapies.https://journals.lww.com/10.4103/ijpm.ijpm_1274_21breast cancersneoadjuvant treatmentstem cell markersstem cellstumor regression grade |
| spellingShingle | Zuhal Gucin Nur Buyukpinarbasili Melin Ozgun Gecer Yeliz Emine Ersoy Haci Mehmet Turk Seyma Yildiz Direnc Ozlem Aksoy Stem cell markers: A guide to neoadjuvant therapy in breast carcinomas Indian Journal of Pathology and Microbiology breast cancers neoadjuvant treatment stem cell markers stem cells tumor regression grade |
| title | Stem cell markers: A guide to neoadjuvant therapy in breast carcinomas |
| title_full | Stem cell markers: A guide to neoadjuvant therapy in breast carcinomas |
| title_fullStr | Stem cell markers: A guide to neoadjuvant therapy in breast carcinomas |
| title_full_unstemmed | Stem cell markers: A guide to neoadjuvant therapy in breast carcinomas |
| title_short | Stem cell markers: A guide to neoadjuvant therapy in breast carcinomas |
| title_sort | stem cell markers a guide to neoadjuvant therapy in breast carcinomas |
| topic | breast cancers neoadjuvant treatment stem cell markers stem cells tumor regression grade |
| url | https://journals.lww.com/10.4103/ijpm.ijpm_1274_21 |
| work_keys_str_mv | AT zuhalgucin stemcellmarkersaguidetoneoadjuvanttherapyinbreastcarcinomas AT nurbuyukpinarbasili stemcellmarkersaguidetoneoadjuvanttherapyinbreastcarcinomas AT melinozgungecer stemcellmarkersaguidetoneoadjuvanttherapyinbreastcarcinomas AT yelizemineersoy stemcellmarkersaguidetoneoadjuvanttherapyinbreastcarcinomas AT hacimehmetturk stemcellmarkersaguidetoneoadjuvanttherapyinbreastcarcinomas AT seymayildiz stemcellmarkersaguidetoneoadjuvanttherapyinbreastcarcinomas AT direncozlemaksoy stemcellmarkersaguidetoneoadjuvanttherapyinbreastcarcinomas |